araag2/HINT huggingface dataset:
Clinical trial NCT03251859 (phase 3, status: completed)
Conditions: myocardial infarction
ICD codes: I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8
Drugs: ticagrelor 90 mg, ticagrelor 60 mg
SMILES: CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1, CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1
Eligibility criteria:

        Inclusion Criteria:

          -  provision of informed consent prior to any study specific procedures

          -  diagnosis of acute ST-segment elevation myocardial infarction or acute non-ST-segment
             elevation myocardial infarction according to the Third Universal Definition of
             Myocardial Infarction

          -  index event treatment with percutaneous coronary intervention

          -  male or non-pregnant female, aged 18-80 years old

        Exclusion Criteria:

          -  contraindications for ticagrelor

          -  further coronary revascularization planned during the first 45 days after myocardial
             infarction

          -  indications for chronic treatment with oral anticoagulant or low-molecular-weight
             heparin

          -  active bleeding

          -  history of intracranial hemorrhage

          -  recent gastrointestinal bleeding (within 30 days)

          -  history of coagulation disorders

          -  history of moderate or severe hepatic impairment

          -  history of major surgery or severe trauma (within 3 months)

          -  active neoplastic disease

          -  patient requiring dialysis

          -  chronic inflammatory disease

          -  current therapy with strong CYP3A inhibitors or strong CYP3A inducers
Clinical trial NCT03252353 (phase 3, status: active, not recruiting)
Conditions: acromegaly
ICD codes: E22.0
Drugs: octreotide capsules, matching placebo
SMILES: [H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Documented evidence of active acromegaly

          -  Treatment with Somatostatin analogs injections (octreotide or lanreotide) for at least
             6 months with a stable dose for at least the last three months of therapy

          -  Biochemically controlled

        Exclusion Criteria:

          -  Patients taking injections of long-acting Somatostatin Receptor Ligands (SRLs) not as
             indicated in the label

          -  Pituitary surgery within six months

          -  Conventional or stereotactic pituitary radiotherapy any time in the past

          -  Patients who previously participated in CH-ACM-01 or OOC-ACM-302

          -  Any clinically significant uncontrolled concomitant disease

          -  Symptomatic cholelithiasis

          -  Pegvisomant, within 24 weeks

          -  Dopamine agonists, within 12 weeks

          -  Pasireotide, within 24 weeks
Clinical trial NCT03253887 (phase 3, status: completed)
Conditions: infection, catheter-related, central line-associated bloodstream infection (clabsi), pediatric
ICD codes: R63.31, R63.32, G47.33, Z68.51, Z68.54, Z68.52, Z68.53
Drugs: ethanol-lock
SMILES: CC(C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Pediatric surgery patients;

          -  Weight: 2 Kg or more;

          -  Using non-tunneled double-lumen polyurethane central venous catheter;

          -  CVC inserted at operation room, Pediatric Intensive Care Unit (PICU) or Neonatal
             Intensive Care Unit (NICU);

          -  CVC adequately positioned (checked by radioscopy ou radiography);

          -  CVC implanted within a maximum of 24 hours.

        Exclusion Criteria:

          -  Patients whose catheters had been inserted under emergency situations;

          -  Patients in a critical condition (those requiring continuous fluid/drug infusion
             through both lumens);

          -  Patients with a history of hypersensitivity or allergic reactions to ethanol were
             excluded from the study.
Clinical trial NCT03255330 (phase 3, status: withdrawn)
Conditions: chronic pain due to trauma, spinal cord injuries
ICD codes: P15.8, T07.XXXS, P12.89, P13.1, P14.3, T07.XXXA, T07.XXXD
Drugs: gabapentin, metamizol, tramadol
SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1, CN(CS(O)(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1, COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
Reason stopped: 
    no participant enrolled
  
Eligibility criteria:

        Inclusion Criteria:

          1. Men and women, age 18 - 65 years

          2. Signed written informed consent

          3. Patients after complete/non-complete spinal lesion, after surgery

          4. Patients with spinal cord trauma caused mechanically demanding (due a injury of a bone
             fragment, a disk, a translation spinal canal)

          5. Patient willing and able to comply with the study protocol

          6. Male and females with a highly effective method of birth control plus an additional
             barrier method

        Exclusion Criteria:

          1. Patients with spinal cord lesion ischemic etiology

          2. Pregnant women, nursing or childbearing age with a positive pregnancy test input

          3. Patients unable or unwilling to comply with the study protocol

          4. Acute pancreatitis in 1 year from the start of the study

          5. Chronic pancreatitis in the case history

          6. Active or uncontrolled infectious diseases

          7. Hypersensitivity to any component of the investigational product

          8. Active autoimmune disease

          9. Serious neurological disease with the incidence chronic neuropathic pain
Clinical trial NCT03257813 (phase 3, status: completed)
Conditions: primary open angle glaucoma, ocular hypertension
ICD codes: H40.1130, H40.1131, H40.1132, H40.1133, H40.1134, H40.1110, H40.1111, H40.053, H40.051, H40.052, H40.059
Drugs: pro-122, krytantek ofteno®
SMILES: CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O, CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  male or female.

          -  obtained in the external consultation.

          -  With diagnosis primary of open-angle glaucoma and / or hypertension classified as
             mild, moderate or severe glaucomatous damage, users of Krytantek Ofteno® at least two
             months prior to inclusion and under control of the target IOP.

          -  informed consent.

        Exclusion Criteria:

        General Criteria

          1. Subjects with topical or systemic medication that interferes decisively in the results
             of the study. (Such as topical immunomodulators, lacrimal point tamponade,
             corticosteroids, ocular hypotensives other than those listed above, artificial tears
             with preservative).

          2. Subjects (female) with an active sex life who are not using a contraceptive method.

          3. Female Subjects in pregnancy or breastfeeding.

          4. Female subjects with positive urine pregnancy test.

          5. Positive drug addiction (verbal interrogation).

          6. Subjects who have participated in any clinical research study in the last 40 days.

          7. Legally or mentally disabled subjects to give informed consent for their participation
             in this study.

          8. Subjects who can not comply with the appointments or with all the requirements of the
             protocol.

        Ophthalmologic criteria

          1. Subject with only one eye with vision.

          2. Subjects with visual capacity 20/200 or worse.

          3. Subjects with a narrow-angle history without treatment, with or without total or
             partial closure of the angle in either eye.

          4. Subjects with corneal abnormalities that prevent applanation tonometry.

          5. Subjects with ocular surgery or ocular trauma 6 months prior to inclusion.

          6. Any ocular laser surgery 3 months prior.

          7. Any uncontrolled or progressive retinal disease.

          8. Inflammatory diseases of any kind.

          9. Contact lens wearers.

         10. Subjects with a history of hypersensitivity to any of the ingredients of the research
             product or its analogues.
Clinical trial NCT03268005 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: faster-acting insulin aspart, insulin aspart, insulin degludec, metformin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria: - Male or female, age equal to or above 18 years at the time of signing
        informed consent. - Diagnosed with type 2 diabetes mellitus for 10 years or longer prior to
        screening (Visit 1). - Treated with a basal-bolus insulin regimen for 1 year or longer
        prior to the day of screening (Visit 1). A basal-bolus insulin regimen is defined as basal
        insulin once or twice daily and bolus insulin analogue taken with meals at least 3 times
        daily. Treatment with premixed insulin or soluble insulin combination is not considered a
        basal-bolus regimen. - Treated with or without oral antidiabetic drugs including extended
        release formulations. - HbA1c 7.0-10.0% (both inclusive) as assessed by central laboratory
        at screening (Visit 1). Exclusion Criteria: - Any of the following: myocardial infarction,
        stroke, hospitalization for unstable angina or transient ischaemic attack within the past
        180 days prior to the day of screening (Visit 1). - Subjects presently classified as being
        in New York Heart Association (NYHA) Class IV. - Planned coronary, carotid or peripheral
        artery revascularisation known on the day of screening (Visit 1). - Treatment with
        injectable GLP-1 receptor agonists in a period of 90 days prior to screening (Visit 1). -
        Anticipated initiation or change in concomitant medications (for more than 14 consecutive
        days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid
        hormones, or corticosteroids).
Clinical trial NCT03290378 (phase 3, status: completed)
Conditions: pain management
ICD codes: Z30.8, Z30.9, Z31.89, Z31.9, Z45.42, Z73.89, Z73.9
Drugs: tramadol
SMILES: COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
Eligibility criteria:

        Key Inclusion Criteria:

          -  The patient is male or female 18-75 years of age undergoing unilateral first
             metatarsal bunionectomy surgery

          -  Willing to give consent and able to understand the study procedures

          -  Female patients must be of non-childbearing potential or be practicing a highly
             effective contraception

          -  The patient must be willing to be housed in a healthcare facility and able to receive
             parenteral analgesia for at least 72 hours after surgery.

          -  The patient meets definition of American Society of Anesthesiologists (ASA) Physical
             Class 1, or 2.

        Exclusion Criteria:

          -  Patient is not expected to receive a continuous infusion nerve block as described in
             the Post-Op anesthetic procedures protocol

          -  Patient is undergoing bilateral or revision bunionectomy surgery

          -  The patient has allergy or hypersensitivity (or is intolerant) to opioids or tramadol
             The patient has known physical dependence on opioids

          -  The patient has taken other prior/concurrent chronic medications that have not been at
             a stable dose for at least 2 weeks prior to screening

          -  The patient is taking herbal or dietary supplements or medications that are moderate
             or strong inhibitors of CYP2D6 or CYP3A4 or inducers of CYP3A4

          -  The patient has taken monoamine oxidase (MAO) inhibitors, trazodone, or
             cyclobenzaprine within 14 days prior to surgery

          -  The patient cannot be withdrawn from medications (at least 7 days prior to surgery)
             that may lower the seizure threshold (e.g. anti-psychotic agents, MAOI inhibitors) or
             which increase serotonergic tone (e.g. selective serotonin reuptake inhibitors
             (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic
             antidepressants, triptans).

          -  The patient has a history of epilepsy, or is known to be susceptible to seizures

          -  The patient has a history of Long QT Syndrome or a relative with this condition

          -  The patient has expressed suicidal ideation or is considered to be at risk of suicide.

          -  The patient is morbidly obese (body mass index [BMI] ≥ 40 kg/m2) or has documented
             sleep apnea requiring pharmacological or device intervention.

          -  Clinically significant abnormalities in the judgement of the Investigator

          -  The patient was administered an investigational product within 30 days prior to
             Screening.

          -  The patient has previously participated in a clinical study with AVE-901.
Clinical trial NCT03308799 (phase 3, status: completed)
Conditions: psoriasis vulgaris
ICD codes: L40.0
Drugs: mc2-01 cream, cal/bdp combination, cream vehicle
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Provided written informed consent

          -  Generally healthy males or non-pregnant females, of any race or ethnicity, who are at
             least 18 years of age at the time of screening

          -  Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6
             months duration that involves the trunk and/or limbs that is amenable to topical
             treatment with a maximum of 100 g of trial medication per week

          -  Have a PGA of disease severity of mild or moderate on the body (trunk and/or limbs)

          -  An mPASI score of at least 2

          -  Have a treatment area involving 2- 30% of the body surface area (BSA)

        Exclusion Criteria:

          -  Current diagnosis of unstable forms of psoriasis

          -  Other inflammatory skin disease in the treatment area that may confound the evaluation
             of the psoriasis vulgaris

          -  Presence of pigmentation, extensive scarring, pigmented lesions or sunburn in the
             treatment areas

          -  Planned exposure to either natural or artificial sunlight

          -  History of hypersensitivity to any component of the test product or reference product

          -  Current or past history of hypercalcemia, vitamin D toxicity, severe renal
             insufficiency, or severe hepatic disorders

          -  Systemic treatment with biological therapies

          -  Use of systemic treatments that suppress the immune system and other systemic
             chemotherapeutic antineoplastic therapy within 4 weeks prior to the baseline visit and
             during the trial

          -  Use of phototherapy within 4 weeks prior to Visit 1/Baseline and during the trial;

          -  Use of topical treatments, except for emollients and non-medicated shampoos, with a
             possible effect on psoriasis within 2 weeks prior to Visit 1/Baseline

          -  Clinical signs of skin infection with bacteria, viruses, or fungi

          -  Known Human Immunodeficiency Virus (HIV) infection

          -  Any chronic or acute medical condition that may pose a risk to the safety of the
             subject, or may interfere with the assessment of safety or efficacy in this trial
Clinical trial NCT03308968 (phase 3, status: completed)
Conditions: migraine prophylaxis
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: fremanezumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  The participant has a diagnosis of migraine with onset at ≤50 years of age.

          -  Body weight ≥45 kilograms.

          -  The participant has a history of migraine for ≥12 months prior to screening.

          -  Women of childbearing potential (WOCBP) whose male partners are potentially fertile
             (that is; no vasectomy) must use highly effective birth control methods for the
             duration of the study and the follow-up period and for 6.0 months after
             discontinuation of investigational medicinal product (IMP)

          -  Men must be sterile, or if they are potentially fertile/reproductively competent (not
             surgically [that is; vasectomy] or congenitally sterile) and their female partners are
             of childbearing potential, must use, together with their female partners, acceptable
             birth control methods for the duration of the study and for 6.0 months after
             discontinuation of the investigational medicinal product (IMP).

               -  Additional criteria apply, please contact the investigator for more information.

        Exclusion Criteria:

          -  At the time of screening visit, participant is receiving any preventive migraine
             medications, regardless of the medical indication for more than 5 days and expects to
             continue with these medications.

          -  Participant has received onabotulinumtoxinA for migraine or for any medical or
             cosmetic reasons requiring injections in the head, face, or neck during the 3 months
             before screening visit.

          -  The participant has used an intervention/device (for example; scheduled nerve blocks
             and transcranial magnetic stimulation) for migraine during the 2 months prior to
             screening.

          -  The participant uses triptans/ergots as preventive therapies for migraine.

          -  Participant uses non-steroidal anti-inflammatory drugs (NSAIDs) as preventive therapy
             for migraine on nearly daily basis for other indications. Note: Low dose aspirin (for
             example; 81 mg) used for cardiovascular disease prevention is allowed.

               -  Additional criteria apply, please contact the investigator for more information.
Clinical trial NCT03345914 (phase 3, status: completed)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: dupilumab, matching placebo
SMILES: CCO, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Key Inclusion Criteria:

          1. Diagnosis of AD according to the American Academy of Dermatology consensus criteria
             (Eichenfield 2003) at screening visit

          2. Chronic AD diagnosed at least 1 year prior to the screening visit

          3. IGA = 4 at screening and baseline visits

          4. EASI ≥21 at the screening and baseline visits

          5. BSA ≥15% at screening and baseline visits

          6. Documented recent history (within 6 months before the baseline visit) of inadequate
             response to topical AD medication(s)

          7. At least 11 (of a total of 14) applications of a stable dose of topical emollient
             (moisturizer) twice daily during the 7 consecutive days immediately before the
             baseline visit

        Key Exclusion Criteria:

          1. Participation in a prior dupilumab clinical study

          2. Treatment with a systemic investigational drug before the baseline visit

          3. Treatment with a topical investigational drug within 2 weeks prior to the baseline
             visit

          4. Treatment with crisabarole within 2 weeks prior to the baseline visit

          5. History of important side effects of medium potency topical corticosteroids (e.g,
             intolerance to treatment, hypersensitivity reactions, significant skin atrophy,
             systemic effects), as assessed by the investigator or patient's treating physician

          6. Treatment with a topical calcineurin inhibitor (TCI) within 2 weeks prior to the
             baseline visit

          7. Having used any of the following treatments within 4 weeks before the baseline visit,
             or any condition that, in the opinion of the investigator, is likely to require such
             treatment(s) during the first 4 weeks of study treatment:

               1. Immunosuppressive/immunomodulating drugs (e.g, systemic corticosteroids,
                  cyclosporine, mycophenolate-mofetil, interferon gamma, Janus kinase inhibitors,
                  azathioprine, methotrexate, etc.)

               2. Phototherapy for AD

          8. Treatment with biologics, as follows:

               1. Any cell-depleting agents including but not limited to rituximab:

                  within 6 months before the baseline visit, or until lymphocyte and CD 19+
                  lymphocyte count returns to normal, whichever is longer

               2. Other biologics: within 5 half-lives (if known) or 16 weeks before the baseline
                  visit, whichever is longer

          9. Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit

         10. Body weight <15 kg at baseline

        Note: Other Inclusion/ Exclusion criteria apply
Clinical trial NCT03345979 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone palmitate
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Has a diagnosis of schizophrenia

          -  Requires acute treatment for symptoms of schizophrenia

          -  Willing and able to be confined to an inpatient study unit for up to 3-4 weeks

          -  Has experienced at least one previous hospitalization for schizophrenia

          -  Has been able to achieve outpatient status for more than 3 months in the past year

          -  Has a body mass index (BMI) between 18.0 and 40.0 kg/m^2

          -  Resides in a stable living situation when not hospitalized

          -  Has an identified reliable caregiver (for example, family member)

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Poses a current suicide risk

          -  Pregnant, planning to become pregnant, or breastfeeding

          -  Initiated first antipsychotic treatment within the past 12 months

          -  Has received a long-acting injectable antipsychotic in the past 3 months

          -  Has participated in a clinical study involving any investigational product within the
             past 3 months, or is currently participating in a clinical study involving an
             investigational product.

          -  A positive urine drug test for drugs of abuse

          -  Additional criteria may apply